(Q37115384)

18 August 2017

1 reference

title

Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth (English)

1 reference

18 August 2017

1 reference

A Munguia

1

1 reference

18 August 2017

T Ota

series ordinal

2

1 reference

18 August 2017

T Miest

series ordinal

3

1 reference

18 August 2017

S J Russell

series ordinal

4

1 reference

18 August 2017

publication date

20 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

15

1 reference

18 August 2017

issue

10

1 reference

18 August 2017

page(s)

797-806

1 reference

https://scigraph.springernature.com/pub.10.1038/gt.2008.45

18 August 2017

exact match

0 references

cites work

Multiple myeloma: an odyssey of discovery

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Vaccine-associated measles pneumonitis in an adult with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Recent progress in the battle between oncolytic viruses and tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Stem cell collection and gene transfer in Fanconi anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Oncolytic measles viruses for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Systemic therapy of myeloma xenografts by an attenuated measles virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

The human CD46 molecule is a receptor for measles virus (Edmonston strain)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Oncolytic measles virus targets high CD46 expression on multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Marrow stromal cells as stem cells for nonhematopoietic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Approaches to utilize mesenchymal progenitor cells as cellular vehicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Migratory fate and differentiation of blood monocyte subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Virus infection of dendritic cells: portal for host invasion and host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Adoptive-cell-transfer therapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Synergistic antitumor effects of immune cell-viral biotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

NK cells in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Measles-virus-neutralizing antibodies in intravenous immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Lifetime of plasma cells in the bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Chemokine requirements for B cell entry to lymph nodes and Peyer's patches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Follicular stromal cells and lymphocyte homing to follicles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Germinal-center organization and cellular dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Cellular niches controlling B lymphocyte behavior within bone marrow during development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Homing of antibody secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Expression and function of chemokine receptors in human multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

7 January 2021

Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

7 January 2021

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

7 January 2021

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

7 January 2021

History of oncolytic viruses: genesis to genetic engineering

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

7 January 2021

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

7 January 2021

Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

7 January 2021

Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

7 January 2021

Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

7 January 2021

Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.45

7 January 2021

Identifiers

DOI

10.1038/GT.2008.45

1 reference

Dimensions Publication ID

18 August 2017

1041453726

0 references

1 reference